What did Oxford brain scanner research reveal about apathetic students compared to motivated ones?
Counterintuitively, apathetic university students showed far greater activity in their brains than motivated students during the same decision-making task. In a study conducted at Oxford University, Dr. Masud Husain and colleagues recruited students across a spectrum of motivation levels and scanned their brains as they made effort-reward decisions. The regions most active in apathetic participants were the basal ganglia and frontal lobes — areas central to evaluating whether an action is worth the cost.
The interpretation is striking: apathetic individuals are not doing less thinking — they are doing more. Their brains expend significantly more energy calculating whether a given effort is worth the expected reward. That cognitive cost itself becomes a barrier. By the time the brain has finished running those calculations, the moment to act has often passed. Motivation, then, is not simply a matter of willpower. It is a measure of how efficiently the brain resolves the effort-versus-reward equation.
This research connects directly to clinical reality. David, a patient studied by Husain, lost all motivation after two small strokes in his basal ganglia — strokes so subtle they were invisible on standard imaging, visible only on high-resolution scans. He stopped listening to music he had always loved, not because he disliked it, but because the internal calculation of effort versus reward no longer resolved in favor of action. The Oxford scanner findings with students mirror exactly what happened to David at a neurological level.
These findings also carry implications for dementia research. Husain's work at the Dementia Research Group at Oxford has established that people who develop apathy in older age have twice the chance of developing dementia in the next ten years compared to those with normal motivation levels. Apathy, long dismissed as laziness or low mood, is increasingly understood as a clinically meaningful signal — one the brain sends well before memory deteriorates. You can explore the full episode on Listenly.
"For David, the effort of putting the music systems together was not worth the reward of being able to listen to something pleasurable — and in David's case, very few things were worth the effort." — Masud Husain, Habits and Hustle, Episode 579
About Masud Husain
Masud Husain is recognised as one of the world's leading neurologists in the study of memory, motivation, and cognitive decline. He co-leads the Dementia Research Group at Oxford University — the same institution where he trained — bringing together decades of clinical work with some of the most rigorous brain research currently underway. He also serves as editor-in-chief of Brain, one of the most respected peer-reviewed journals in neurology, a role that positions him at the centre of the field's evolving understanding of neurological conditions. What distinguishes Husain's approach is his insistence on studying real patients rather than relying solely on theoretical models: his cases, including David's, have directly shaped how apathy and motivation are understood as early markers of neurological change. His work on the effort-reward calculus underpinning apathy — including the Oxford brain scanner study described in this episode — offers a neurological framework that challenges how clinicians, researchers, and individuals think about motivation loss in everyday life.
See also
Beyond physical factors like exercise, sleep, and stress management, Dr. Husain identifies three psychosocial factors as equally important: maintaining a sense of purpose, staying socially connected, and continuing to engage in mentally stimulating activities throughout life.
Dr. Husain explains that high-performing individuals often maintain cognitive function longer because of greater cognitive reserve, coping strategies, and neurological resilience — but when decline does set in, it can appear more abrupt because so much had been compensated for over time.
Dr. Husain notes that approximately one third of people with depression do not respond to serotonin-based antidepressants. He explains that clinical trials exploring dopaminergic drugs offer a promising avenue for these patients, given the central role dopamine plays in motivation and reward processing.